影像生物标志物在非酒精性脂肪性肝病中的作用:临床应用最新进展与未来研究方向
非酒精性脂肪性肝病(NAFLD)全球约十亿人患病,肝活检虽为评估疾病严重程度金标准,但具侵入性、观察者间变异大且伴随疼痛、感染乃至罕见死亡等不良反应,因患者数量庞大而难以普及。本综述讨论用于量化肝脏脂肪和肝纤维化的不同无创影像模态,探讨现有模态检测非酒精性脂肪性肝炎的局限,并比较各种基于影像的弹性成像模态检测晚期纤维化或肝硬化的效能及诊断特征。
要点
- NAFLD全球约十亿人患病,无创评估疾病严重程度工具急需。
- 肝活检为金标准但具侵入性、观察者间变异大,可致疼痛、感染及罕见死亡。
- 综述讨论量化肝脂肪和肝纤维化的无创影像模态及其检测非酒精性脂肪性肝炎的局限。
核心结论
- 肝活检虽为NAFLD疾病严重程度评估金标准,但因侵入性、观察者间变异及不良反应而不切实际,急需无创评估工具。
- 近二十年来无创影像在NAFLD评估方面取得巨大进展。
研究设计与样本
- 综述,讨论用于量化肝脏脂肪和肝纤维化的不同无创影像模态。
主要发现
- NAFLD是主要公共卫生问题,全球约十亿人患病。
- 肝活检具侵入性、观察者间变异大,并与疼痛、感染及罕见死亡等不良反应相关。
- 因NAFLD患者数量庞大,肝活检不切实际。
局限性
- 当前模态检测NAFLD进展形式即非酒精性脂肪性肝炎存在局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Non-alcoholic fatty liver disease (NAFLD) is a major public health problem afflicting approximately one billion individuals worldwide. Liver biopsy is considered the gold standard for assessment of liver disease severity in patients with NAFLD. However, it is invasive, has high inter-observer variability, and is associated with adverse effects, including pain, infection and, albeit rarely, death. It is also impractical because of the large number of individuals who have NAFLD. Therefore, tools to non-invasively assess disease severity in NAFLD are urgently needed. Over the last two decades, tremendous advances have been made in the assessment of NAFLD by non-invasive imaging. In this review, we will discuss the different non-invasive imaging modalities available to quantify liver fat and liver fibrosis. We will also discuss the limitations of current modalities to detect the progressive form for NAFLD, termed non-alcoholic steatohepatitis. Finally, we will discuss the comparative efficacy of various imaging-based elastographic modalities for detection of advanced fibrosis or cirrhosis, as well as their diagnostic characteristics.
引用
- Loomba R. Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions. J Hepatol. 2017. PMID: 29203392. doi:10.1016/j.jhep.2017.11.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。